<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741624</url>
  </required_header>
  <id_info>
    <org_study_id>0165</org_study_id>
    <nct_id>NCT00741624</nct_id>
  </id_info>
  <brief_title>Pain Reduce Following Refractive Surgery</brief_title>
  <official_title>Mitigating Pain Following Refractive Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FORSIGHT Vision3</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FORSIGHT Vision3</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      applying a material over the exposed stromal bed following refractive surgery to prevent
      local abrasion and significantly reduce pain
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessed for pain at 1, 2 and 4 hours and 1, 3 and 5 days. Comparison to non study eye will
      be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain relief</measure>
    <time_frame>1 week</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bilateral post refractive surgery subject</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bandage</intervention_name>
    <description>one application for one week</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who underwent bilateral PRK for myopic correction.

          2. Age 18-60.

          3. Patient complains of significant pain.

          4. Patients able to understand the requirements of the study and willing to follow study
             instructions, to provide written informed consent to participate, and who agree to
             comply with all study requirements, including the required study follow-up visits

        Exclusion Criteria:

          1. Any other anterior segment abnormality other than that associated with PRK.

          2. Any abnormalities associated with the eye lids.

          3. Prior laser treatment of the retina.

          4. Any ophthalmic surgery performed within three (3) months prior to study excluding PRK.

          5. Diagnosis of glaucoma.

          6. Active diabetic retinopathy.

          7. Clinically significant inflammation or infection within six (6) months prior to study.

          8. Uncontrolled systemic disease (e.g., diabetes, hypertension, etc.) in the opinion of
             the Investigator.

          9. Participation in any study involving an investigational drug within the past 30
             calendar days, or ongoing participation in a study with an investigational device.

         10. Specifically known intolerance or hypersensitivity to contact lenses.

         11. A medical condition, serious intercurrent illness, or extenuating circumstance that
             would significantly decrease study compliance, including all prescribed follow-up.

         12. Any condition that, in the opinion of the investigator, would jeopardize the safety of
             the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Verssano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sorasky Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sorasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Yair Alster</name_title>
    <organization>Forsignt Vision</organization>
  </responsible_party>
  <keyword>refractive surgery</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

